乌帕替尼治疗克罗恩病和溃疡性结肠炎的真实世界持续性、有效性和安全性:西班牙全国性研究(Ureal研究)
这项西班牙多中心回顾性研究纳入100例炎症性肠病患者(68例克罗恩病、32例溃疡性结肠炎),评估乌帕替尼的真实世界持续性、有效性和安全性。中位随访7.6个月时23例停药,克罗恩病(vs溃疡性结肠炎)和启动乌帕替尼时年龄低于40岁与停药相关;第8、12、52周临床缓解率分别为59%、64%、42%。43例报告不良事件,其中11例严重。
要点
- 克罗恩病(vs溃疡性结肠炎)与年龄低于40岁与乌帕替尼停药相关(HR分别为3.7和2.4)。
- 第12周临床缓解的相关因素为溃疡性结肠炎诊断、基线轻中度活动和不吸烟。
- 剂量升级使60%复发患者重获缓解;43例报告不良事件,11例严重。
核心结论
- 乌帕替尼对高度难治性炎症性肠病患者有效且安全,即使既往接受过Janus激酶抑制剂治疗。
研究设计与样本
- 西班牙全国性多中心回顾性研究,纳入2022年12月31日前且至少早于招募日期12周接受乌帕替尼的炎症性肠病患者100例(克罗恩病68例、溃疡性结肠炎32例)。
主要发现
- 患者既往接受过中位4种先进治疗;中位随访7.6个月时23例停药。
- 多变量分析中,克罗恩病(vs溃疡性结肠炎)与停药相关(HR 3.7;95%CI 1.04-12.9),启动乌帕替尼时年龄低于40岁与停药相关(HR 2.4;95%CI 1.0-5.8)。
- 炎症性肠病临床缓解率第8周为59%、第12周为64%、第52周为42%。
- 既往暴露于托法替布的溃疡性结肠炎患者(n=25)第12周临床缓解比例为78%、第52周为50%。
- 第12周临床缓解的相关因素为溃疡性结肠炎诊断(OR 4.6;95%CI 1.3-17)、基线轻中度活动(OR 8;95%CI 1.1-56)和不吸烟(OR 4.4;95%CI 1.5-13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario. METHODS: Retrospective multicenter study of patients with IBD who received upadacitinib before 31st December 2022 and at least 12 weeks before the recruitment date. Clinical effectiveness was assessed based on partial Mayo score for ulcerative colitis (UC) and Harvey-Bradshaw index for Crohn's disease (CD). RESULTS: We included 100 patients (68 with CD, and 32 with UC). Patients had previously received a median of 4 advanced therapies. Twenty-three discontinued the treatment (median follow-up 7.6 months). CD (vs UC) (hazard ratio 3.7; 95% confidence interval [CI]: 1.04-12.9) and age below 40 years at upadacitinib initiation (hazard ratio 2.4; 95% CI: 1.0-5.8) were associated with treatment discontinuation in multivariable analysis. Clinical remission for IBD was achieved in 59% of patients at week 8, 64% at week 12, and 42% at week 52. The proportion of patients with UC previously exposed to tofacitinib (n = 25) who achieved clinical remission was 78% at week 12, and 50% at week 52. Factors associated with clinical remission at week 12 were UC diagnosis (odds ratio [OR] 4.6; 95% CI: 1.3-17), mild or moderate activity at baseline (OR 8; 95% CI: 1.1-56), and not smoking (OR 4.4; 95% CI: 1.5-13). Dose escalation recaptured remission in 60% of patients with relapse. Eighty percent of patients with active immune-mediated diseases or extraintestinal manifestations improved with upadacitinib. Forty-three patients reported adverse events, 11 of them serious. DISCUSSION: Upadacitinib is effective and safe for treating patients with highly refractory IBD, even in previously treated with Janus kinase inhibitors.
引用
- García MJ, Brenes Y, Vicuña M, et al. Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study). Am J Gastroenterol. 2024. PMID: 39588977. doi:10.14309/ajg.0000000000003243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。